1.Mechanism of Breg cell in tumor immune escape and related therapeutic targets
Xibo WANG ; Baowen TIAN ; Shiqiao CHEN
Journal of International Oncology 2025;52(2):107-112
Tumor cells can escape the surveillance and attack of the immune system, namely immune escape. In recent years, regulatory B (Breg) cell have attracted much attention in researches about tumor immunity. Breg cell plays an important role in tumor immune escape by secreted various cytokines. Mechanistic progress has been made in this field, which provides more targets and ideas for tumor clinical treatment. However, the phenotypic classification of Breg cells and its complex mechanism in tumor immunity still need to be systematically analyzed.
2.Th17 Cells and IL-17 are Increased in Patients with Brain Metastases from the Primary Lung Cancer
HE GAIPING ; ZHANG BIN ; ZHANG BAOWEN ; QIAO LIANGJIE ; TIAN ZHONGLAN ; ZHAI GUOYAN ; XIN XIANWEI ; YANG CHUN ; LIU PEIGANG ; ZHANG YONG ; XU LINGLING
Chinese Journal of Lung Cancer 2013;(9):476-481
Background and objective Th17 cells are important T helper cells, which are characterized by their production of IL-17. hT17 cells play an important role in host defense against microbial infections, autoimmune diseases and cancer. hTe aim of this study is to investigate the percentage of hT17 in peripheral blood lymphocyte and the level of IL-17 in serum and cerebrospinal lfuid (CSF) in patients with brain metastases from lung cancer. Methods Twenty-two patients with brain metastases from lung cancer and 20 health controls were analyzed. hTe percentage of hT17 cell was detected with lfow cytometry using CD3+CD4+IL-23R+marker, the level of IL-17 was measured with ELISA method. Results hTe percentage of hT17 cells in patients with brain metastases from lung cancer was 4.65%±0.72%, which was remarkably higher than that in con-trols (2.71%±0.54%, P=0.04). hTere was no signiifcant difference between non-small cell lung cancer (NSCLC) patients and small cell lung cancer (SCLC) patients. Serum IL-17 was remarkably increased in patients with brain metastases from lung can-cer (117.4±16.43 pg/mL vs 72.55±8.19 pg/mL, P=0.02). No signiifcant difference of the serum IL-17 was observed between NSCLC and SCLC patients. hTe level of IL-17 in CSF from patients with brain metastases from lung cancer was signiifcant higher than that from lung cancer patients without brain metastases (73.21±7.52 pg/mL vs 50.25±8.04 pg/mL, P=0.04). Con-clusion hT17 cells and IL-17 increase in patients with brain metastases from lung cancer. It may involve in the pathogenesis of brain metastases from lung cancer.

Result Analysis
Print
Save
E-mail